Carfilzomib
Who holds supplier records for Carfilzomib? 19 organisations hold a current record for Carfilzomib: an active US FDA Type II Drug Master File. A further 4 organisations have only historical (inactive) DMF filings. Recorded organisation countries for current records: China (8), India (6) and Netherlands (1); not recorded for 4.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Carfilzomib: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/carfilzomib
Reading the evidence
- 19 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 9 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Carfilzomib expires 29 Oct 2041. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (19)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Carfilzomib. Country is the organisation's recorded country, not necessarily the manufacturing site.
- BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITEDIndiaActive DMF 32406 · latest filing Dec 2017
- CHONGQING CARELIFE PHARMACEUTICAL CO LTDChinaActive DMF 38180 · latest filing May 2023
- CHONGQING MIDECO PHARMACEUTICAL CO LTDActive DMF 41199 · latest filing Jan 2025
- Chongqing Sintaho Pharmaceutical Co., Ltd.ChinaActive DMF 40891 · latest filing Mar 2025
- Dr. Reddy's Laboratories Ltd.India Company GMP cert on recordActive DMF 30402 · latest filing Mar 2016
- Hetero Labs LimitedIndia Company GMP cert on recordActive DMF 40268 · latest filing Feb 2025
- Intas Pharmaceuticals Ltd.India Company GMP cert on recordActive DMF 35083 · latest filing Sept 2020
- Jiangsu Hansoh Pharmaceutical Group Company LimitedChina Company GMP cert on recordActive DMF 41263 · latest filing Mar 2025
- Jiangsu Xidi Pharmaceuticals Co., LtdChinaActive DMF 38486 · latest filing Sept 2023
- Laurus Labs LimitedIndia Company GMP cert on recordActive DMF 30115 · latest filing Mar 2016
- LIANYUNGANG RUNZHONG PHARMACEUTICAL CO LTDChinaActive DMF 41029 · latest filing Jan 2025
- MSN Laboratories Private LimitedIndia Company GMP cert on recordActive DMF 29671 · latest filing Aug 2015
- POLYMED THERAPEUTICS INCActive DMF 30357 · latest filing Feb 2016
- Qilu Pharmaceutical Co., Ltd.China Company GMP cert on recordActive DMF 29770 · latest filing Sept 2015
- Shandong New Time Pharmaceutical Co LtdCompany GMP cert on recordActive DMF 38290 · latest filing May 2023
- Sichuan Huiyu Pharmaceutical Co., Ltd.China Company GMP cert on recordActive DMF 40758 · latest filing Nov 2024
- TAPI NL BVNetherlandsActive DMF 30124 · latest filing Jan 2016
- TONGSHENG PHARMACEUTICAL (JINGMEN) CO LTDActive DMF 42402 · latest filing Aug 2025
- Wisdom Pharmaceutical Co., LtdChinaActive DMF 43372 · latest filing Dec 2025
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Historical records (4)
Organisations whose Type II DMFs for Carfilzomib are no longer active. These show a past filing, not current supply.
Show all 4 historical records
- China · Inactive DMF 38169 · filed Apr 2023
- CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTDInactive DMF 31276 · filed Dec 2016
- India · Inactive DMF 29750 · filed Jan 2016
- CHONGQING PHARMACEUTICAL RESEARCH INSTITUTE CO LTDInactive DMF 30162 · filed Dec 2015
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (5 listed products contain Carfilzomib). The latest listed patent expires 29 Oct 2041. The latest listed exclusivity runs to 22 Nov 2028. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Carfilzomib is a protein active pharmaceutical ingredient (ChEMBL CHEMBL451887).
Chemical identity
- IUPAC name
- (2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide
- Canonical SMILES
- CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4
- InChIKey
- BLMPQMFVWMYDKT-NZTKNTHTSA-N
- Synonyms
- Carfilzomib, Kyprolis, NSC-758252, PR-171, CHEBI:65347, carfilzomibum, PR171, RefChem:57059, L01XX45, Carfilzomib (PR-171), Carfilzomib (PR171), Carfilzomib [USAN]
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Proteasome Inhibitor
- Mechanism of action
- Proteasome Inhibitors
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Carfilzomib?
19 organisations hold an active US FDA Type II Drug Master File or a CEP for Carfilzomib: BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (India), CHONGQING CARELIFE PHARMACEUTICAL CO LTD (China), CHONGQING MIDECO PHARMACEUTICAL CO LTD, Chongqing Sintaho Pharmaceutical Co., Ltd. (China), Dr. Reddy's Laboratories Ltd. (India), Hetero Labs Limited (India), Intas Pharmaceuticals Ltd. (India) and Jiangsu Hansoh Pharmaceutical Group Company Limited (China), and 11 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Carfilzomib Drug Master Files are active?
BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (DMF 32406), CHONGQING CARELIFE PHARMACEUTICAL CO LTD (DMF 38180), CHONGQING MIDECO PHARMACEUTICAL CO LTD (DMF 41199), Chongqing Sintaho Pharmaceutical Co., Ltd. (DMF 40891), Dr. Reddy's Laboratories Ltd. (DMF 30402), Hetero Labs Limited (DMF 40268), Intas Pharmaceuticals Ltd. (DMF 35083) and Jiangsu Hansoh Pharmaceutical Group Company Limited (DMF 41263) and 11 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Carfilzomib records mean?
4 organisations have only inactive Type II DMFs for Carfilzomib. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does the FDA Orange Book list patents for products containing Carfilzomib?
Yes. The latest patent listed for an approved US product containing Carfilzomib expires 29 Oct 2041, across 5 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Carfilzomib supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Carfilzomib?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.